CEP164

Across TCGA pan-cancer cohorts, CEP164 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEP164 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEP164 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP164 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where CEP164 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.990	0.902	.011	20	view →
CCRCC	DFS	Median	II,III,IV	0.798	1.000	.008	6	view →
LUAD	DFS	Median	II,III,IV	0.790	0.888	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CEP164–HNSC (DFS)

Open the HNSC breakdown →